Medicines for Crohn’s disease and ulcerative colitis to reach $10.2bn overall in 2018

 
 
vg
vg
LONDON - Nov. 21, 2014 - PRLog -- A new report by visiongain (https://www.visiongain.com/) forecasts the worldwide drug market for treating inflammatory bowel disease will reach $10.2bn in 2018. That revenue forecast and others appear in Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025 (https://www.visiongain.com/Report/1353/Inflammatory-Bowel-Diseases-%28IBD%29-World-Drug-Industry-and-Market-2015-2025), published in November 2014. Visiongain is a business information publisher and consultancy in London, UK.

That investigation predicts the IBD treatment market will grow in revenues owing to the increasing use of biological (http://www.visiongain.com/Sector/8/Pharma) therapies (biologics), e.g. monoclonal antibodies (mAbs). Although biologics account for a small part of prescriptions worldwide in 2014, they dominate the market for revenue generation and hold 60% of the global market. The strength of that market is also reflected in the 37 new treatments undergoing clinical development to treat IBD and nine proposed biosimilars of adalimumab and infliximab, at present the leading therapies for inflamed lower intestine disorders.

Sandra Wenas, a pharmaceutical industry analyst in visiongain, said: “The world IBD drug market will show strong sales growth over the next five years from 2014. The increased use of biologics will be the main sales driver in that market. Cost containment may form a restraint, though. Still, as more doctors advocate the top-down approach and more studies justify the cost effectiveness of monoclonal antibodies, biologic therapies are expected to gain higher usage, to claim 67% of that treatment market’s revenues by 2025. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries. The cost advantage of aminosalicylates will be more pronounced in those regions.”

That study also finds that developed world markets make up the majority of the overall world IBD market, but emerging national markets, particularly India and China, will also show strong revenue growth from 2014. That overall market holds high commercial potential and strong research and development to yield future therapies, also expanding that industry and market.

The new investigation shows revenue forecasts to 2025 at overall world market, submarket, product and national level. As well as predicting the overarching world market, that work forecasts its five main components:

Aminosalicylates
Antibiotics
Corticosteroids
Biologic therapies (biological drugs)
Immunomodulators.

That report also predicts revenues of 17 leading inflammatory bowel disease treatments to 2025, including Remicade, Humira, Asacol and the newly approved treatments Uceris, Simponi and Entyvio.

The analysis includes trends and forecasted revenues for national markets. There it studies the US, Japan, Germany, France, the UK, Spain, Italy, Brazil, Russia, India and China. That investigation also assesses products in development, showing R&D for treating those gastrointestinal disorders. The work also gives interviews with two authorities.

Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover medical devices, diagnostics and pharmaceuticals.

For further information about this report please visit https://www.visiongain.com/Report/1353/Inflammatory-Bowel-Diseases-%28IBD%29-World-Drug-Industry-and-Market-2015-2025

Contact: Sara Peerun on sara.peerun@visiongainglobal.com Tel: +44 (0) 20 7336 6100

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail tosara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Contact
Sara Peerun
***@visiongainglobal.com
End
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share